355 results on '"Cheok, Meyling"'
Search Results
2. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study
3. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia
4. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
5. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
6. Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis
7. Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature
8. MPAgenomics : An R package for multi-patients analysis of genomic markers
9. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
10. The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress
11. Tetraspanin CD81 promotes leukemia stem cell function and represents a new therapeutic vulnerability in acute myeloid leukemia
12. The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia
13. Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity
14. UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia
15. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML
16. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes
17. Supplementary Data Figure Legends from CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy
18. Supplementary Data Figures 1-4 from CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy
19. Data from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
20. Data from CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy
21. Supplementary Table 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
22. Supplementary Figure 1 from Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity
23. Correction: The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress
24. LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1-Mutated Acute Myeloid Leukemia: An ALFA Study
25. A 17-gene stemness score for rapid determination of risk in acute leukaemia
26. Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure
27. Prognostic impact of ABCA3 expression in adult and pediatric acute myeloid leukemia: an ALFA-ELAM02 joint study
28. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
29. Ex vivo drug sensitivity profiling‐guided treatment of a relapsed pediatric mixed‐phenotype acute leukemia with venetoclax and azacitidine
30. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in AML
31. UBTFtandem duplications define a distinct subtype of adult de novo acute myeloid leukemia
32. Multiparametric Flow Cytometry Evaluation of CD200L/CD200R- LSC/NK Synapse Including Leukemia Stem Cell (LSC) Fraction As a Potential Therapeutic Target and Marker of NK Cell Exhaustion in Pediatric AML-Conect-AML French Collaborative Network
33. Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
34. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
35. Tetraspanin CD81 Supports Cancer Stem Cell Function and Represents a Therapeutic Vulnerability in Acute Myeloid Leukemia
36. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
37. Classification of CEBPA mutated acute myeloid leukemia by GATA2 mutations
38. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
39. Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications
40. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells
41. Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy
42. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile
43. Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
44. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
45. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment
46. Neurofibromatosis-1 gene deletions and mutations in de novo adult acute myeloid leukemia
47. Genetic polymorphisms in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study
48. Pharmacogenomic considerations of xenograft mouse models of acute leukemia
49. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia
50. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.